

### Issue 1 Complexity of data

| Description of problem  | Description of proposed amendment | Result of amended model or expected impact on the result (if applicable) |
|---|-----------------------------------|--|
| The information provided was unintelligible to the majority of the commentators. Moreover, in the time that had been allowed to feedback to NICE, it has not been possible for these commentators to consult individuals with relevant expertise. |                                   |  |

### Issue 2 Stalled clinical guidance

| Description of problem  | Description of proposed amendment                   | Result of amended model or expected impact on the result (if applicable) |
|---|---|--|
| Clinical guidance on ibandronic acid and zoledronic acid has been delayed due to issues surrounding TAG160 and 161. | Select these compounds under "topics for guidance". |  |

### Issue 3 Cost reduction

| Description of problem                          | Description of proposed amendment                  | Result of amended model or expected impact on the result (if applicable) |
|---|--|--|
| Non-generics will be available for prescribing. | NICE to consider the resulting reduction in costs. |  |